VSee Health, Inc. (VSEE)
NASDAQ: VSEE · Real-Time Price · USD
0.6059
-0.0441 (-6.78%)
At close: Nov 25, 2025, 4:00 PM EST
0.6059
0.00 (0.00%)
Pre-market: Nov 26, 2025, 5:41 AM EST
VSee Health Revenue
VSee Health had revenue of $3.93M in the quarter ending September 30, 2025, with 7.30% growth. This brings the company's revenue in the last twelve months to $14.00M, up 64.23% year-over-year. In the year 2024, VSee Health had annual revenue of $10.42M with 80.74% growth.
Revenue (ttm)
$14.00M
Revenue Growth
+64.23%
P/S Ratio
0.68
Revenue / Employee
$93,679
Employees
154
Market Cap
18.99M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 10.42M | 4.66M | 80.74% |
| Dec 31, 2023 | 5.77M | - | - |
| Dec 31, 2022 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionVSEE News
- 21 hours ago - VSee Health's iDoc Division Powers Ahead: Delivering on Major Contracts and Igniting Revenue Growth! - Accesswire
- 5 days ago - VSee Health Names Dr. Milton Chen as Chairman to Drive AI Infrastructure Growth - Accesswire
- 8 days ago - VSEE Health, Inc. Delivers Robust Q3 2025 Revenue Growth Amid Telehealth Expansion: Total Revenues Reach $3.98 Million, Up 19% Year-Over-Year - Accesswire
- 14 days ago - VSee Health Pioneers Telehealth Expansion with FedRAMP Authorization and ICU Robot Integration, Fueling 2025 Growth Surge - Accesswire
- 19 days ago - VSee Engages Philippine Health Leaders and Former VP Robredo in Southeast Asia expansion effort - Accesswire
- 21 days ago - VSee Health Secures Three-Year Platform Services Agreement with the Region's Sole Level 1 Trauma Center and Academic Health System - Accesswire
- 25 days ago - VSee Health Accelerates Teleradiology Domination - Accesswire
- 27 days ago - Vsee stock soars on FedRAMP news but ‘immediate' dilution risk warrants selling - Invezz